Therefore, beginning with the selection of the ligand, conformational changes in AhR, binding of cofactors, post-translational modifications that alter the chromatin architecture, and cross-talk of AhR signaling with other pathways leads to the simultaneous regulation of multiple signaling pathways—which ultimately can contribute to the potential attenuation or progression of NAFLD. The gene discussed is AHR; the disease is metabolic dysfunction-associated steatotic liver disease.